ES2487633T3 - Métodos y composiciones para prevenir o tratar condiciones oftálmicas - Google Patents
Métodos y composiciones para prevenir o tratar condiciones oftálmicas Download PDFInfo
- Publication number
- ES2487633T3 ES2487633T3 ES10812524.6T ES10812524T ES2487633T3 ES 2487633 T3 ES2487633 T3 ES 2487633T3 ES 10812524 T ES10812524 T ES 10812524T ES 2487633 T3 ES2487633 T3 ES 2487633T3
- Authority
- ES
- Spain
- Prior art keywords
- arg
- dmt
- phe
- lys
- tyr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 108010048898 phenylalanyl-arginyl-phenylalanyllysinamide Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 71
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 41
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 15
- 108010018625 phenylalanylarginine Proteins 0.000 description 10
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 description 5
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 5
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 4
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OZSNQMIQTHGXPJ-QMMMGPOBSA-N (2s)-2-amino-3-[(2-aminobenzoyl)amino]propanoic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C1=CC=CC=C1N OZSNQMIQTHGXPJ-QMMMGPOBSA-N 0.000 description 2
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WJJGAKCAAJOICV-JTQLQIEISA-N (2s)-2-(dimethylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical group CN(C)[C@H](C(O)=O)CC1=CC=C(O)C=C1 WJJGAKCAAJOICV-JTQLQIEISA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical group CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23644009P | 2009-08-24 | 2009-08-24 | |
| US236440P | 2009-08-24 | ||
| US23774509P | 2009-08-28 | 2009-08-28 | |
| US237745P | 2009-08-28 | ||
| US34847010P | 2010-05-26 | 2010-05-26 | |
| US348470P | 2010-05-26 | ||
| PCT/US2010/046338 WO2011025734A1 (en) | 2009-08-24 | 2010-08-23 | Methods and compositions for preventing or treating ophthalmic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2487633T3 true ES2487633T3 (es) | 2014-08-22 |
Family
ID=43628336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20156769T Active ES2964555T3 (es) | 2009-08-24 | 2010-08-23 | Péptido para uso en la prevención o tratamiento de la degeneración macular |
| ES10812524.6T Active ES2487633T3 (es) | 2009-08-24 | 2010-08-23 | Métodos y composiciones para prevenir o tratar condiciones oftálmicas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20156769T Active ES2964555T3 (es) | 2009-08-24 | 2010-08-23 | Péptido para uso en la prevención o tratamiento de la degeneración macular |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8470784B2 (de) |
| EP (17) | EP4302829A3 (de) |
| JP (7) | JP6120399B2 (de) |
| CN (3) | CN105056206A (de) |
| CA (1) | CA2772094C (de) |
| DK (2) | DK3708178T3 (de) |
| ES (2) | ES2964555T3 (de) |
| FI (1) | FI3708178T3 (de) |
| HK (5) | HK1172833A1 (de) |
| HR (1) | HRP20231277T1 (de) |
| HU (1) | HUE064800T2 (de) |
| LT (1) | LT3708178T (de) |
| PL (2) | PL3708178T3 (de) |
| PT (2) | PT2470191E (de) |
| SI (2) | SI2470191T1 (de) |
| WO (1) | WO2011025734A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8930846B2 (en) | 2010-10-01 | 2015-01-06 | Z124 | Repositioning applications in a stack |
| EP3753534A1 (de) | 2008-09-29 | 2020-12-23 | Edwards Lifesciences CardiAQ LLC | Herzklappe |
| US8337541B2 (en) | 2008-10-01 | 2012-12-25 | Cardiaq Valve Technologies, Inc. | Delivery system for vascular implant |
| JP2012523894A (ja) | 2009-04-15 | 2012-10-11 | カルディアック バルブ テクノロジーズ，インコーポレーテッド | 血管インプラント及びその配設システム |
| EP4302829A3 (de) | 2009-08-24 | 2024-03-27 | Stealth BioTherapeutics Inc. | Peptid zur verwendung bei der vorbeugung oder behandlung von makula degenerationugenleiden |
| EP3560508A1 (de) | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Kombinationstherapien mit verwendung von cyclosporin und aromatischen kationischen peptiden |
| WO2011137363A1 (en) * | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
| WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| EP2688579A4 (de) * | 2011-03-24 | 2015-10-21 | Univ Cornell | Aromatisch-kationische peptide und verwendungen davon |
| US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
| US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
| CN102327600A (zh) * | 2011-09-14 | 2012-01-25 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 用于预防和治疗辐射损伤的rx31肽 |
| US8878794B2 (en) | 2011-09-27 | 2014-11-04 | Z124 | State of screen info: easel |
| EP3466439A1 (de) * | 2011-12-09 | 2019-04-10 | Stealth Peptides International, Inc. | Aromatisch-kationische peptide und verwendungen davon |
| CA2865317A1 (en) * | 2012-02-22 | 2013-08-29 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| US9636378B2 (en) * | 2012-03-30 | 2017-05-02 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment neuropathy |
| US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
| AU2013296493B2 (en) * | 2012-08-02 | 2018-04-26 | Stealth Biotherapeutics Inc. | Methods for treatment of atherosclerosis |
| JP6284341B2 (ja) * | 2012-10-24 | 2018-02-28 | 国立大学法人東京農工大学 | 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| DK2961420T3 (da) * | 2013-03-01 | 2019-10-07 | Stealth Biotherapeutics Corp | Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom |
| EP3673913A1 (de) * | 2013-03-01 | 2020-07-01 | Stealth Biotherapeutics Corp | Verbindungen zur behandlung von mitochondrialen erkrankungen |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
| US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
| US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
| WO2015017781A1 (en) * | 2013-08-01 | 2015-02-05 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating leber's hereditary optic neuropathy |
| CA2920735A1 (en) * | 2013-08-12 | 2015-02-19 | Stealth Biotherapeutics Corp | Combination therapy for the treatment of ischemia-reperfusion injury |
| CN105764533A (zh) * | 2013-10-25 | 2016-07-13 | 儿童医疗中心有限公司 | 治疗或预防视网膜血管疾病的方法 |
| WO2015084875A1 (en) * | 2013-12-02 | 2015-06-11 | Stealth Peptides International, Inc. | Compositions and methods for treating vitiligo |
| CA2936146A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| JP6692795B2 (ja) | 2014-04-10 | 2020-05-13 | ランケナー インスティテュート フォー メディカル リサーチ | 眼疾患および眼障害の治療のための方法および組成物 |
| EP3149035A4 (de) * | 2014-05-28 | 2018-05-16 | Stealth BioTherapeutics Corp | Therapeutische zusammensetzungen mit kleinen therapeutischen molekülen und verwendungen davon |
| BR112017012655B1 (pt) * | 2014-12-19 | 2022-11-01 | Kemin Industries, Inc | Uso de moléculas bioativas |
| EP3397271B1 (de) | 2015-12-30 | 2021-11-03 | Marshall University Research Corporation | Zusammensetzungen und verfahren zur behandlung von retinopathie |
| CN115160402A (zh) | 2016-03-11 | 2022-10-11 | 隐形生物治疗公司 | 结晶盐形式 |
| KR102578476B1 (ko) * | 2016-04-11 | 2023-09-13 | 유니버시티 오브 캔버라 | 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물 |
| CA3020393A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| EP3606938A1 (de) | 2017-04-05 | 2020-02-12 | Stealth BioTherapeutics Corp | Kristalline salzformen von boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| CN111372576A (zh) * | 2017-11-17 | 2020-07-03 | 塞尔利克斯生物私人有限公司 | 用于治疗眼部病症的组合物和方法 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| EP3787749A4 (de) * | 2018-05-03 | 2022-01-26 | Alimera Sciences, Inc. | Verfahren zur behandlung von netzhauterkrankungen |
| WO2020018455A1 (en) * | 2018-07-16 | 2020-01-23 | Stealth Biotherapeutics Corp | Compositions and methods for the treatment of traumatic optic neuropathy |
| CA3113528A1 (en) * | 2018-09-21 | 2020-03-26 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
| WO2020214990A1 (en) * | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
| JP2020174859A (ja) * | 2019-04-17 | 2020-10-29 | 学校法人日本医科大学 | 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法 |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| WO2022138842A1 (ja) * | 2020-12-24 | 2022-06-30 | 参天製薬株式会社 | エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 |
| IL312199A (en) * | 2021-10-20 | 2024-06-01 | Stealth Biotherapeutics Inc | Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions |
| WO2023069255A1 (en) * | 2021-10-20 | 2023-04-27 | Stealth Biotherapeutics Inc. | Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions |
| WO2023086873A1 (en) * | 2021-11-10 | 2023-05-19 | Reverspah Llc | Methods and compositions for treating cancer |
| CN114099678A (zh) * | 2021-11-23 | 2022-03-01 | 浙江大学 | 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂 |
| KR102662922B1 (ko) * | 2022-05-31 | 2024-05-03 | 주식회사 세네릭스 | 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| EP0350221B1 (de) * | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin-Analoge, deren Herstellungsverfahren, pharmazeutische Zusammensetzungen und Methode zur therapeutischen Behandlung unter Verwendung der Analoge |
| US5674980A (en) * | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| DE69630918T2 (de) * | 1995-06-09 | 2004-10-28 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Matrix für Iontophorese |
| US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| WO1999029721A1 (en) * | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| EP1071414A1 (de) * | 1998-04-24 | 2001-01-31 | Mitokor | Verbindungen und verfahren zur behandlung von mitochondrialererkrankungen |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| SE9900961D0 (sv) * | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
| CA2386540A1 (en) * | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| US20050192215A1 (en) * | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
| JP2001270832A (ja) * | 2000-03-27 | 2001-10-02 | Ito En Ltd | 網膜障害予防剤 |
| US7498297B2 (en) * | 2000-07-18 | 2009-03-03 | Cornell Research Foundation | Medicinal uses of mu-opioid receptor agonists |
| US6900178B2 (en) * | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US20070015146A1 (en) * | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
| AU2003259793A1 (en) * | 2002-08-14 | 2004-03-03 | Medical College Of Georgia Research Institute, Inc. | Methods and compositions for treatment of macular and retinal disease |
| US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20060172972A1 (en) | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| EP3842055A1 (de) * | 2003-02-04 | 2021-06-30 | Cornell Research Foundation, Inc. | Verwendung von aromatisch kationischem peptid |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| CN100506841C (zh) * | 2003-05-01 | 2009-07-01 | 科内尔研究基金会 | 将分子递送到细胞的方法和载体复合物 |
| US7232824B2 (en) * | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
| US7550439B2 (en) * | 2004-01-23 | 2009-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| SI1755616T1 (sl) | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| JP4760111B2 (ja) | 2005-04-26 | 2011-08-31 | 株式会社セガ | 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体 |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| JP2007043629A (ja) * | 2005-06-30 | 2007-02-15 | Sony Corp | グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置 |
| CA2615360A1 (en) | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
| EP3549594A1 (de) * | 2005-09-16 | 2019-10-09 | Cornell Research Foundation, Inc. | Aromatisch-kationisches peptid zur verwendung in einem verfahren zur reduzierung der cd36-expression |
| US20090270315A1 (en) | 2005-10-05 | 2009-10-29 | Aqumen Biopharmaceuticals K.K. | Method of inhibiting angiogenesis by using ephrin b2 |
| US20070259377A1 (en) * | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
| TW200744627A (en) | 2006-02-21 | 2007-12-16 | Pfizer Prod Inc | Methods for the treatment of macular degeneration and related eye conditions |
| EP2021026A1 (de) * | 2006-04-14 | 2009-02-11 | Novartis AG | Verwendung von il-i-antikörpern zur behandlung von augenleiden |
| US20080027082A1 (en) * | 2006-06-19 | 2008-01-31 | Berthold Hocher | Use of adenosine a1 antagonists in radiocontrast media induced nephropathy |
| DE102006042329B4 (de) * | 2006-09-01 | 2008-08-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas |
| EP2104509A4 (de) | 2006-12-11 | 2010-03-24 | Univ Utah Res Found | Zusammensetzungen und verfahren zur behandlung von pathologischer angiogenese und gefässpermeabilität |
| JP2008195655A (ja) * | 2007-02-14 | 2008-08-28 | Kitasato Institute | 糖尿病白内障の治療剤 |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| ES2370751T3 (es) | 2007-05-25 | 2011-12-22 | Santen Pharmaceutical Co., Ltd | Agente profiláctico o terapéutico para la degeneración macular asociada a la edad. |
| EP3272353A1 (de) * | 2008-02-07 | 2018-01-24 | Cornell University | Verfahren zur vorbeugung oder behandlung von insulinresistenz |
| EP3741381B1 (de) * | 2008-02-26 | 2024-04-24 | Cornell University | Peptide zur verwendung zur prävention oder behandlung von akutem nierenversagen |
| EP3906933A1 (de) | 2009-03-20 | 2021-11-10 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosin-lys-phe-nh2 zur verwendung bei der vorbeugung von sekundären komplikationen von verbrennungsverletzungen |
| FR2945540B1 (fr) | 2009-05-15 | 2012-06-08 | Rhodia Operations | Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede |
| EP2464371B1 (de) | 2009-08-12 | 2016-03-16 | Cornell University | Verfahren zur vorbeugung oder behandlung des stoffwechselsyndroms |
| EP4302829A3 (de) * | 2009-08-24 | 2024-03-27 | Stealth BioTherapeutics Inc. | Peptid zur verwendung bei der vorbeugung oder behandlung von makula degenerationugenleiden |
| CN104725472A (zh) * | 2010-01-25 | 2015-06-24 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
| CA2790823A1 (en) * | 2010-02-26 | 2011-09-01 | University Of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP2942354A1 (de) | 2010-05-03 | 2015-11-11 | Stealth Peptides International, Inc. | Aromatische-kationische peptide und verwendungen davon |
| US20150118315A1 (en) | 2011-06-14 | 2015-04-30 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US10293020B2 (en) * | 2013-06-27 | 2019-05-21 | Stealth Biotherapeutics Corp. | Peptide therapeutics and methods for using same |
| US20160199437A1 (en) * | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
| US20160228491A1 (en) * | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
-
2010
- 2010-08-23 EP EP23194389.5A patent/EP4302829A3/de active Pending
- 2010-08-23 CN CN201510388677.1A patent/CN105056206A/zh active Pending
- 2010-08-23 PL PL20156769.0T patent/PL3708178T3/pl unknown
- 2010-08-23 EP EP17205537.8A patent/EP3338788A1/de not_active Withdrawn
- 2010-08-23 EP EP10812524.6A patent/EP2470191B1/de active Active
- 2010-08-23 EP EP16175746.3A patent/EP3124036A1/de not_active Withdrawn
- 2010-08-23 EP EP18194243.4A patent/EP3485896A1/de not_active Withdrawn
- 2010-08-23 ES ES20156769T patent/ES2964555T3/es active Active
- 2010-08-23 SI SI201030612T patent/SI2470191T1/sl unknown
- 2010-08-23 EP EP18214554.0A patent/EP3524256A1/de not_active Withdrawn
- 2010-08-23 EP EP17183644.8A patent/EP3292868A1/de not_active Withdrawn
- 2010-08-23 HR HRP20231277TT patent/HRP20231277T1/hr unknown
- 2010-08-23 PT PT108125246T patent/PT2470191E/pt unknown
- 2010-08-23 EP EP20156769.0A patent/EP3708178B1/de active Active
- 2010-08-23 PL PL10812524T patent/PL2470191T3/pl unknown
- 2010-08-23 HU HUE20156769A patent/HUE064800T2/hu unknown
- 2010-08-23 PT PT201567690T patent/PT3708178T/pt unknown
- 2010-08-23 EP EP16177723.0A patent/EP3175862A1/de not_active Withdrawn
- 2010-08-23 ES ES10812524.6T patent/ES2487633T3/es active Active
- 2010-08-23 EP EP17194835.9A patent/EP3318264A1/de not_active Withdrawn
- 2010-08-23 EP EP14181858.3A patent/EP2826487A1/de not_active Withdrawn
- 2010-08-23 LT LTEP20156769.0T patent/LT3708178T/lt unknown
- 2010-08-23 EP EP15172384.8A patent/EP2990049A1/de not_active Withdrawn
- 2010-08-23 FI FIEP20156769.0T patent/FI3708178T3/fi active
- 2010-08-23 SI SI201032136T patent/SI3708178T1/sl unknown
- 2010-08-23 EP EP14164726.3A patent/EP2813235A1/de not_active Withdrawn
- 2010-08-23 WO PCT/US2010/046338 patent/WO2011025734A1/en active Application Filing
- 2010-08-23 CN CN2010800481393A patent/CN102625709A/zh active Pending
- 2010-08-23 EP EP18205074.0A patent/EP3494983A1/de not_active Withdrawn
- 2010-08-23 CA CA2772094A patent/CA2772094C/en active Active
- 2010-08-23 JP JP2012526880A patent/JP6120399B2/ja active Active
- 2010-08-23 DK DK20156769.0T patent/DK3708178T3/da active
- 2010-08-23 DK DK10812524.6T patent/DK2470191T3/da active
- 2010-08-23 EP EP15174180.8A patent/EP2957291A1/de not_active Withdrawn
- 2010-08-23 US US12/861,593 patent/US8470784B2/en active Active
- 2010-08-23 EP EP16186448.3A patent/EP3150215A1/de not_active Withdrawn
- 2010-08-23 CN CN201610861402.XA patent/CN107412722A/zh active Pending
- 2010-08-23 EP EP15177582.2A patent/EP2962695A1/de not_active Withdrawn
-
2013
- 2013-01-03 HK HK13100064.6A patent/HK1172833A1/xx unknown
- 2013-05-17 US US13/897,070 patent/US9023807B2/en active Active
-
2015
- 2015-03-27 US US14/671,538 patent/US9549963B2/en active Active
- 2015-06-16 HK HK15105695.0A patent/HK1204958A1/xx unknown
- 2015-07-20 HK HK16105839.6A patent/HK1217900A1/zh unknown
- 2015-07-20 HK HK15106883.0A patent/HK1206258A1/xx unknown
- 2015-10-02 JP JP2015197004A patent/JP6332757B2/ja active Active
-
2017
- 2017-01-09 US US15/401,527 patent/US10188692B2/en active Active
- 2017-05-29 JP JP2017105602A patent/JP6381737B2/ja active Active
-
2018
- 2018-06-01 HK HK18107246.7A patent/HK1247821A1/zh unknown
- 2018-07-31 JP JP2018143180A patent/JP2018162329A/ja active Pending
-
2019
- 2019-01-25 US US16/258,521 patent/US20200061147A1/en not_active Abandoned
-
2020
- 2020-06-02 JP JP2020096157A patent/JP2020128431A/ja active Pending
- 2020-07-02 US US16/919,777 patent/US11612633B2/en active Active
-
2021
- 2021-10-18 JP JP2021170354A patent/JP2022001609A/ja active Pending
-
2023
- 2023-02-09 US US18/107,640 patent/US20230346874A1/en active Pending
- 2023-08-11 US US18/448,650 patent/US11944662B2/en active Active
- 2023-10-18 JP JP2023179375A patent/JP2023179733A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2487633T3 (es) | Métodos y composiciones para prevenir o tratar condiciones oftálmicas | |
| US20190209641A1 (en) | Methods for preventing or treating metabolic syndrome | |
| CN101627049B (zh) | 合成酞酰胺 | |
| TWI374030B (en) | Use of melanocortins to treat insulin sensitivity | |
| TW487711B (en) | Conjugates of lipophilic moieties and peptides | |
| KR20160121608A (ko) | 전립선 비대증 치료 및 예방용 조성물 | |
| CN102397558A (zh) | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 | |
| CN106866814A (zh) | Dpp‑4抑制剂 | |
| CA2643239A1 (en) | Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides | |
| KR20180004752A (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
| JP3668950B2 (ja) | ペプチドと、その合成方法と、それをベースにした医薬品 | |
| TWI305778B (en) | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use | |
| US20180042983A1 (en) | Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same | |
| NO317919B1 (no) | Tri-, tetra-, penta-, og polypeptider samt deres anvendelse for fremstilling av et farmasoytisk preparat til behandling av depresjon | |
| KR20180058843A (ko) | 짧은 합성 펩티드 및 그의 용도 | |
| CN105585612B (zh) | 八肽修饰的地塞米松、制备、纳米结构和应用 | |
| WO2016062234A1 (zh) | 八肽修饰的地塞米松,其制备,纳米结构和应用 | |
| WO2017101144A1 (zh) | 脂肪组织靶向多肽及其制备方法和应用 | |
| CA2992971C (en) | Peptides useful for treating cancer | |
| JP2022513305A (ja) | アディポネクチン由来ペプチドを含む発毛促進用組成物 | |
| Fang et al. | Cardiovascular effects of intravenous administered 26RFa, a novel RFamide peptide ligand for GPR103, in anaesthetised rats | |
| US7713935B2 (en) | Compounds that modulate TRH actions | |
| CN105504013B (zh) | 八肽修饰的地塞米松、其制备、纳米结构和应用 | |
| Trudeau et al. | Asma and David Cherait1, 2, 3*, Vaudry1, 4* Julie Maucotel1, 4, Benjamin Lefranc1, 4, Jeroˆme Leprince1, 4 | |
| WO2010150082A2 (en) | Use of chromogranin a and of peptidic derivatives thereof in the treatment of inflammation |